LAST_NAME FIRST_NAME Poster # Castiglioni Claudia 1 Belter Lisa 2 Belter Lisa 3 Dabbous Omar 4 Bassano Michela 5 De Amicis Ramona 6 Bertoli Simona 7

Size: px
Start display at page:

Download "LAST_NAME FIRST_NAME Poster # Castiglioni Claudia 1 Belter Lisa 2 Belter Lisa 3 Dabbous Omar 4 Bassano Michela 5 De Amicis Ramona 6 Bertoli Simona 7"

Transcription

1 LAST_NAME FIRST_NAME Poster # Castiglioni Claudia 1 Belter Lisa 2 Belter Lisa 3 Dabbous Omar 4 Bassano Michela 5 De Amicis Ramona 6 Bertoli Simona 7 Chen Tai-Heng 8 Mastella Chiara 9 Babb Jaanai 10 Eagen Shelly 11 Rothman Jennifer 12 Goodwin Ashley 13 Crippa Patricia 14 Townsend Elise 15 Dunaway Young Sally 16 Duong Tina 17 Alfano Lindsay 18 Castiglioni Claudia 19 Salazar Rachel 20 LoMauro Antonella 21 Monges Soledad 22 Dixon Stacy 23 Otto Louise 24 Shieh Perry 25 Sumner Charlotte 26 Tizzano Eduardo 27 Bullivant Joanne 28 Bullivant Joanne 29 O'Connor Nicole 30 Zappa Grazia 31 Zappa Grazia 32 LaMarca Nicole 33 Farrar Michelle 34 Farrar Michelle 35 Glascock Jackie 36 Newcomb Tara 37 Swoboda Kathryn 38 Swoboda Kathryn 39 Ascadi Gyula 40 Bharucha Goebel Diana 41 Brady Caitlin 42 Coskery Shelley 43 Elsheikh Bakri 44 Ikuta Ichiro 45 LaMarca Nicole 46

2 Romero Danielle 47 Rao Vamshi 48 Toops Jeannie 49 Kundrat Katherine 50 Cruz Rosangel 51 Cruz Rosangel 52

3 Title CAREGIVER BURDEN IN SPINAL MUSCULAR ATROPHY PARENTS IN CHILE Survival and Ventilation among those with Type I SMA: Results from the 2017 Cure SMA Membership Sur Cure SMA Membership: Findings from the 2018 Membership Survey Economic Burden of Infant-Onset (Type 1) Spinal Muscular Atrophy: A Retrospective Claims Database An Vitamins intake in italian children with spinal muscular atrophy type 1 and 2 Is Fat Free Mass amount associated to protein intake in children with Spinal Muscular Atrophy Type I? Nutritional status and body composition of children with spinal muscular atrophy type 1 before pharmac Hospitalization and Emergency Room Visits among Children with Spinal Muscular Atrophy: Experience of Multidisciplinary Italian Program for Early Parental Empowerment (PEPE) in SMA type 0 and type I (SMA1 Characterization of Infant and Early Childhood Spinal Muscular Atrophy Patients and Their Transitions of Improving Patient Access to Multidisciplinary Clinical Care for Patients with Neuromuscular Disorders A modified physiotherapeutic scoliosis specific exercise program (Schroth method) and night bracing stab Performance of the six minute walk test in pediatric neuromuscular disease: Review and comparison to h Exploratory study for comparison of passive gait training methods in nonabulatory SMA children Supported standing in SMA Types 1 and 2: Head rotation control and respiratory support predict meanin Scoliosis is Negatively Associated with Motor Function in Children with Later-Onset SMA Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Feasibility for More than just fun and games: Can the ACTIVE workspace volume video game quantify meaningful chang Use of inertial sensors in motor function assessment in spinal muscular atrophy type 3. An exploratory st Prospective Quantitative Study of Passive Lower Extremity Range of Motion (ROM) in Spinal Muscular At Impaired ribcage muscles function alters ribcage structure in spinal muscular atrophy (SMA) children Wide spectrum of age at onset and clinical variability in SMA infants and children with 3 SMN2 copies. Diagnosis of 5q-related SMA in an asymptomatic woman after undergoing routine SMN1 carrier screenin MR imaging of muscle as a biomarker for disease progression in SMA Quantitative Determination of SMN2 Copy Number using Next Generation Sequencing and Correlation to Neurofilament as a Potential Biomarker for Spinal Muscular Atrophy: Rationale Based on Animal and Hum Update on SMN1 mutations in Spanish SMA patients: description of new rare stop and splicing mutations Collaborative Data by TREAT-NMD Registries to support post-marketing surveillance in Spinal Muscular A Aligning spinal muscular atrophy registries worldwide for post-marketing surveillance The Updated Family Guide for Spinal Muscular Atrophy Two case reports of spinal muscular atrophy Type II with Autism Spectrum Disorders Cognitive Development (IQ), Language Comprehension and Motor Functioning in SMA1 Children using AA Spinal Muscular Atrophy: Cases of Normal Non-Verbal Receptive Vocabulary and Reasoning Skills in Non- "The whole game is changing and you've got hope": Decision making in Spinal Muscular Atrophy care. Newborn Screening Pilot for Diagnosis of SMA/PID by Multiplex qpcr on Guthrie Card DNA Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening Statewide newborn screening for SMA in Utah, implementation and early results The NBSTRN SPOT SMA Longitudinal Population Database Repository (LPDR) Utilization of the Newborn Screening Translational Research Network (NBSTRN): Project Cure SMA Longit Early therapeutic response to Spinraza in SMA type 3 Implementation and Experiences with nusinersen (Spinraza) for infants and children with Spinal Muscular Spinraza and Inpatient Rehabilitation: What's the relationship? Nusinersen Protocol and Treatment of Patients with Spinal Muscular Atrophy (SMA) The Ohio State University Wexner Medical Center (OSUWMC) experience in treating adults with Spinal M Image-guided Spinraza (nusinersen) injection for patients with spinal muscular atrophy: Taking great care Development of a Nusinersen Treatment Program for Spinal Muscular Atrophy at a Large Academic

4 Value of an advanced practice nurse in care coordination of Spinraza treatment for SMA patients. Challenges and outcomes with nusinersen in a wide spectrum of SMA patients: The Lurie Children's Hosp The FAST (Facilitating Access to SMA Treatment) Program at Nationwide Children's Hospital: a Model for Utilizing SATCo to Assess Trunk Control in Patient's with SMA Undergoing Spinraza Treatment Benefit-Risk Survey Results for Spinal Muscular Atrophy Informing Drug Development in SMA Results of Nationwide Survey to Evaluate SMA Clinical Trial Capacity at Sites with Experience Conducting

5 bilized scoliotic curves and improved pulmonary function in young boy with Spinal Muscle Atrophy Type

6

7 3 - A Case Report

22nd Annual SMA Researcher Meeting

22nd Annual SMA Researcher Meeting 22nd Annual SMA Researcher Meeting Thursday June 14, 2018 8:30 AM Welcoming Remarks Jill Jarecki PhD, Cure SMA Chief Scientific Officer Special Session: Clinical and Basic Questions of SMA in the Era of

More information

Kathryn J. Swoboda, MD, FACMG NBSTRN Meeting

Kathryn J. Swoboda, MD, FACMG NBSTRN Meeting Kathryn J. Swoboda, MD, FACMG NBSTRN Meeting SPOT SMA LPDR resource: overview of clinical research forms and overall database Feasibility and utility of a minimal common set of data elements vs. a more

More information

Letter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy

Letter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy TEMPLATE Letter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy Date: [Insert Name of Medical Director] RE: Patient Name [ ] [Insurance Company] Policy Number [ ] [Address]

More information

Prior Authorization Update: Nusinersen

Prior Authorization Update: Nusinersen Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

The 2017 Update of the Standard of Care Recommendations for Spinal Muscular Atrophy

The 2017 Update of the Standard of Care Recommendations for Spinal Muscular Atrophy Richard Finkel, MD Nemours Children s Hospital Orlando, FL, USA Thomas Crawford, MD Johns Hopkins Hospital Baltimore, MD, USA The 2017 Update of the Standard of Care Recommendations for Spinal Muscular

More information

Spinraza (Nusinersen) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)

Spinraza (Nusinersen) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) Line of Business: All Lines of Business Effective Date: August 16, 2017 Spinraza (Nusinersen) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through

More information

Spinal Muscular Atrophy as a Focus Indication for Biomarker Development. Meg Winberg, PhD Spinal Muscular Atrophy Foundation February 26, 2007

Spinal Muscular Atrophy as a Focus Indication for Biomarker Development. Meg Winberg, PhD Spinal Muscular Atrophy Foundation February 26, 2007 Spinal Muscular Atrophy as a Focus Indication for Biomarker Development Meg Winberg, PhD Spinal Muscular Atrophy Foundation February 26, 2007 Why SMA? p Low incidence, but a large orphan indication p Scientifically

More information

Spinal Muscular Atrophy: Case Study. Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting

Spinal Muscular Atrophy: Case Study. Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting Spinal Muscular Atrophy: Case Study Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting approximately one in 6,000 babies. It is estimated that one in every 40 Americans carries

More information

ISIS-SMN Rx Background and Current Status. C. Frank Bennett Sr. VP, Research Isis Pharmaceuticals

ISIS-SMN Rx Background and Current Status. C. Frank Bennett Sr. VP, Research Isis Pharmaceuticals ISIS-SMN Rx Background and Current Status C. Frank Bennett Sr. VP, Research Isis Pharmaceuticals ISIS-SMN Rx : Modulating Splicing of SMN2 to Increase Normal SMN Protein 2 Uniformly 2 -O-methoxyethyl modified

More information

Spinraza (nusinersen)

Spinraza (nusinersen) Spinraza (nusinersen) Policy Number: 5.02.540 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Spinraza

More information

SMA Treatment Access and Clinical Trials Webinar. February 15, 2018

SMA Treatment Access and Clinical Trials Webinar. February 15, 2018 SMA Treatment Access and Clinical Trials Webinar February 15, 2018 Treatment Access Update Current Dosing Metrics December 2017: ~1,900 patients been dosed in US Including those in extension trials and

More information

Spinal Muscular Atrophy in 2017

Spinal Muscular Atrophy in 2017 Spinal Muscular Atrophy in 2017 Leigh Maria Ramos-Platt, MD Children s Hospital of Los Angeles University of Southern California Keck School of Medicine Disclosures MDA Care Center Grant In this presentation,

More information

SMA Treatments and Clinical Trials. Kenneth Hobby, President Mary Schroth, MD, Chief Medical Officer Jill Jarecki, PhD, Chief Scientific Officer

SMA Treatments and Clinical Trials. Kenneth Hobby, President Mary Schroth, MD, Chief Medical Officer Jill Jarecki, PhD, Chief Scientific Officer SMA Treatments and Clinical Trials Kenneth Hobby, President Mary Schroth, MD, Chief Medical Officer Jill Jarecki, PhD, Chief Scientific Officer Agenda Introduction Kenneth Hobby, President Spinraza Update

More information

Association of motor milestones and SMN2 copy and outcome in spinal muscular. atrophy types 0 4

Association of motor milestones and SMN2 copy and outcome in spinal muscular. atrophy types 0 4 jnnp-2016-314292 1 - SUPPLEMENTARY FILE - Methods and additional data on clinical characteristics and motor development Association of motor milestones and SMN2 copy and outcome in spinal muscular atrophy

More information

Spinal Muscular Atrophy Newborn Screening

Spinal Muscular Atrophy Newborn Screening 10.2018 Spinal Muscular Atrophy Newborn Screening Melissa Gibbons, MS, CGC Erica Wright, MS, CGC Clinical Genetics and Metabolism Department of Pediatrics Children s Hospital Colorado/ University of Colorado

More information

SPINRAZA (NUSINERSEN)

SPINRAZA (NUSINERSEN) SPINRAZA (NUSINERSEN) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0059D Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...

More information

CADTH Canadian Drug Expert Committee Recommendation

CADTH Canadian Drug Expert Committee Recommendation CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (FINAL) Nusinersen (Spinraza Biogen Canada Inc.) Indication: Treatment of 5q Spinal Muscular Atrophy RECOMMENDATION: The CADTH

More information

Roche leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics.

Roche leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics. Media Release PRIME designation granted by European Medicines Agency for Roche s risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2017 10/2018 10/2017 Description of Procedure or Service Spinal muscular atrophy

More information

Faculty. W4: Identifying Patients with Rare Disorders Using Administrative Data. O Dan Malone, RPh, PhD University of Arizona

Faculty. W4: Identifying Patients with Rare Disorders Using Administrative Data. O Dan Malone, RPh, PhD University of Arizona W4: Identifying Patients with Rare Disorders Using Administrative Data Faculty O Dan Malone, RPh, PhD University of Arizona O Danny Yeh, PhD Biogen O Ed Armstrong Strategic Therapeutics, LLC O Eric Bell,

More information

Should Universal Carrier Screening be Universal?

Should Universal Carrier Screening be Universal? Should Universal Carrier Screening be Universal? Disclosures Research funding from Natera Mary E Norton MD University of California, San Francisco Antepartum and Intrapartum Management June 15, 2017 Burden

More information

Thomas O. Crawford, MD July 1, Annual Spinal Muscular Atrophy Conference June 29 July 2, 2017 Orlando, FL

Thomas O. Crawford, MD July 1, Annual Spinal Muscular Atrophy Conference June 29 July 2, 2017 Orlando, FL 2017 Annual Spinal Muscular Atrophy Conference June 29 July 2, 2017 Orlando, FL Efficacy and Safety of Nusinersen in Genetically Diagnosed Infants With Presymptomatic Spinal Muscular Atrophy (SMA): Results

More information

When a Threshold Crossing approach may and may not be appropriate: A Case Study in SMA

When a Threshold Crossing approach may and may not be appropriate: A Case Study in SMA When a Threshold Crossing approach may and may not be appropriate: A Case Study in SMA EFSPI Regulatory Statistics Workshop, 24-25 th September 2018 Carol Reid and Uli Burger picture placeholder Outline

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Nusinersen Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 5 References... 5 Effective Date... 10/15/2017 Next

More information

Ambulant & non ambulant (Types 2 & 3) Spinal Muscular Atrophy

Ambulant & non ambulant (Types 2 & 3) Spinal Muscular Atrophy Ambulant & non ambulant (Types 2 & 3) Spinal Muscular Atrophy Mário Miguel Rosa, MD, PhD SAWP, CNSWP (EMA) FMUL, INFARMED Lisbon - Portugal SMA EMA workshop An agency of the European Union Content Relevant

More information

Nusinersen in Pre-symptomatic Infants With Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study

Nusinersen in Pre-symptomatic Infants With Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study 21 st International Congress of the World Muscle Society -8 October, 2016 Granada, Spain Nusinersen in Pre-symptomatic Infants With Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2018 10/2019 10/2018 Description of Procedure or Service Spinal muscular atrophy

More information

Clinical Policy Bulletin: Nusinersen (Spinraza)

Clinical Policy Bulletin: Nusinersen (Spinraza) Clinical Policy Bulletin: Nusinersen (Spinraza) Number: 0915 Policy *Pleasesee amendment forpennsylvaniamedicaidattheendofthiscpb. Note: REQUIRES PRECERTIFICATION.Footnotes for Precertification of nusinersen

More information

Nusinersen Use in Spinal Muscular Atrophy

Nusinersen Use in Spinal Muscular Atrophy Nusinersen Use in Spinal Muscular Atrophy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Slide 1 Evidence in Focus Endorsement and

More information

SMA IS A SEVERE NEUROLOGICAL DISORDER [1]

SMA IS A SEVERE NEUROLOGICAL DISORDER [1] SMA OVERVIEW SMA IS A SEVERE NEUROLOGICAL DISORDER [1] Autosomal recessive genetic inheritance 1 in 50 people (approximately 6 million Americans) are carriers [2] 1 in 6,000 to 1 in 10,000 children born

More information

New Drug Evaluation: Nusinersen Injection, Intrathecal

New Drug Evaluation: Nusinersen Injection, Intrathecal Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Title: Developmental milestones in type I spinal muscular atrophy

Title: Developmental milestones in type I spinal muscular atrophy Accepted Manuscript Title: Developmental milestones in type I spinal muscular atrophy Author: Roberto De Sanctis, Giorgia Coratti, Amy Pasternak, Jacqueline Montes, Marika Pane, Elena S. Mazzone, Sally

More information

2018 F. Hoffmann-La Roche Ltd. All rights reserved.

2018 F. Hoffmann-La Roche Ltd. All rights reserved. PRELIMINARY EVIDENCE FOR PHARMACODYNAMIC EFFECTS OF RG7916 IN JEWELFISH A STUDY IN PATIENTS WITH SPINAL MUSCULAR ATROPHY WHO PREVIOUSLY PARTICIPATED IN A STUDY WITH ANOTHER SMN2-SPLICING TARGETING THERAPY

More information

Implementation of Newborn Screening for Duchenne Muscular Dystrophy.

Implementation of Newborn Screening for Duchenne Muscular Dystrophy. Implementation of Newborn Screening for Duchenne Muscular Dystrophy. Michele A. Lloyd-Puryear, MD, PhD 1, Stuart J Moat, PhD 2, Amy Brower 3, PhD, Annie Kennedy 1, Petra Furu 4, Michael Watson, PhD 3,

More information

CARE CONSIDERATIONS FOR DUCHENNE MUSCULAR DYSTROPHY

CARE CONSIDERATIONS FOR DUCHENNE MUSCULAR DYSTROPHY IMPORTANT NEW UPDATE A Summary of the Report of the DMD Care Considerations Working Group Intended for US healthcare professionals only. CARE CONSIDERATIONS FOR DUCHENNE MUSCULAR DYSTROPHY Full article

More information

Panel II: SMA Drugs in Development

Panel II: SMA Drugs in Development Panel II: SMA Drugs in Development Jinsy Andrews MD, Director of Clinical Research and Development, Cytokinetics Thomas Blaettler MD, Global Clinical Development Team Leader, F. Hoffmann-La Roche Jerry

More information

Value of Physical Therapy TINA DUONG PARENT PROJECT MUSCULAR DYSTROPHY ANNUAL CONFERENCE 28JUN2018

Value of Physical Therapy TINA DUONG PARENT PROJECT MUSCULAR DYSTROPHY ANNUAL CONFERENCE 28JUN2018 Value of Physical Therapy TINA DUONG PARENT PROJECT MUSCULAR DYSTROPHY ANNUAL CONFERENCE 28JUN2018 Disclosures Scientific Advisory Board: Biogen, Cytokinetics, Roche, Acceleron Consultation: Roche, Audentes,

More information

TREAT-NMD Conference 2013

TREAT-NMD Conference 2013 TREAT-NMD Conference 2013 Utility of patient registries for clinical care and post-marketing surveillance Jan Verschuuren Leiden University Medical Centre Newcastle 30 October 1 November 2013 2 Improving

More information

Diagnosis, management and new treatments for Spinal Muscular Atrophy Special Focus: SMA Type 1

Diagnosis, management and new treatments for Spinal Muscular Atrophy Special Focus: SMA Type 1 Diagnosis, management and new treatments for Spinal Muscular Atrophy Special Focus: SMA Type 1 17 th April 2018 Adnan Manzur Consultant Paediatric Neurologist Dubowitz Neuromuscular Centre, GOSH & ICH,

More information

9/30/2017. SMA: Spinal Muscular Atrophy Learning Outcomes: SMA. Prevalence. Review of the diagnosis. Here are the odds

9/30/2017. SMA: Spinal Muscular Atrophy Learning Outcomes: SMA. Prevalence. Review of the diagnosis. Here are the odds SMA: Spinal Muscular Atrophy Learning Outcomes: 1 in 6,000 to 1 in 10,000 but 100% to CRT Kay Koch, OTR/L, ATP The van Halem Group, A Division of VGM kkotrchoa@yahoo.com The participant will be able to

More information

INDUSTRY PERSPECTIVE ON DRUG DEVELOPMENT FOR TYPE 1 SMA

INDUSTRY PERSPECTIVE ON DRUG DEVELOPMENT FOR TYPE 1 SMA INDUSTRY PERSPECTIVE ON DRUG DEVELOPMENT FOR TYPE 1 SMA Kathie M. Bishop, PhD Disclosures: Currently, CSO of Tioga Pharmaceuticals, no activities in SMA; 2009-2015, full-time employee of Ionis Pharmaceuticals,

More information

Evolving therapeutic landscape for inherited neurologic disorders. Kathryn Swoboda, MD HMS Child Neurology Course September

Evolving therapeutic landscape for inherited neurologic disorders. Kathryn Swoboda, MD HMS Child Neurology Course September Evolving therapeutic landscape for inherited neurologic disorders Kathryn Swoboda, MD HMS Child Neurology Course September 5 2017 Disclosures I ve received funding as a consultant for Biogen for clinical

More information

APTA, Academy of Pediatric Physical Therapy (APPT) Research Agenda

APTA, Academy of Pediatric Physical Therapy (APPT) Research Agenda APTA, Academy of Pediatric Physical Therapy (APPT) Research Agenda 2017-2020 Goal of the Research Agenda: To promote research in pediatric physical therapy that advances and enhances health or movement

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 11.28.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder

More information

12th UK Neuromuscular Translational Research Conference Centre for Life, Newcastle

12th UK Neuromuscular Translational Research Conference Centre for Life, Newcastle 12th UK Neuromuscular Translational Research Conference Centre for Life, Newcastle Thursday 4 and Friday 5 April 2019 PROGRAMME Day 1 Thursday 4 April 09:00 09:30 Registration and Coffee 09:30 09:40 Introduction

More information

Rehabilitation and psychosocial aspects in DMD care

Rehabilitation and psychosocial aspects in DMD care Rehabilitation and psychosocial aspects in DMD care Budapest, 18-04-2012 Birgit F. Steffensen, Physiotherapist, PhD The National Danish Rehabilitation Centre for Neuromuscular Diseases Denmark Demographics:

More information

Associate Professor Andrew Kornberg April 2015 MDWA Symposium

Associate Professor Andrew Kornberg April 2015 MDWA Symposium The of Neuromuscular Disease A Neurology Perspective Multifaceted and best using a multidisciplinary approach Genetic counselling begins at diagnosis issues include: Physical Emotional Social Educational

More information

Clinical Trials in Neuromuscular Disease: Lessons Learned and Steps Forward

Clinical Trials in Neuromuscular Disease: Lessons Learned and Steps Forward Clinical Trials in Neuromuscular Disease: Lessons Learned and Steps Forward Course Description: Over 7,000 rare diseases affect an estimated ~30 million Americans. Many of these conditions involve movement

More information

Disclosures Arthur Burghes. SAB AveXis. Performed studies funded by AveXis. Consulted for Novartis

Disclosures Arthur Burghes. SAB AveXis. Performed studies funded by AveXis. Consulted for Novartis Disclosures Arthur Burghes SAB AveXis Performed studies funded by AveXis Consulted for Novartis Type of Biomarker Prognostic Disease Progression Predictive Pharmacodynamic Surrogate Endpoint Definition

More information

Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants With Spinal Muscular Atrophy

Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants With Spinal Muscular Atrophy American Academy of Neurology 2017 69th Annual Meeting April 22 28, 2017 Boston, MA Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants With

More information

Assessing the Needs of the SMA Population: Survey Results of Health Care Providers and Families

Assessing the Needs of the SMA Population: Survey Results of Health Care Providers and Families 559018SGOXXX10.1177/2158244014559018SAGE OpenHalanski et al. research-article2014 Article Assessing the Needs of the SMA Population: Survey Results of Health Care Providers and Families SAGE Open October-December

More information

Pharmacoeconomic Review Report

Pharmacoeconomic Review Report CADTH COMMON DRUG REVIEW Pharmacoeconomic Review Report NUSINERSEN (SPINRAZA) (Biogen Canada Inc.) Indication: Treatment of patients with 5q SMA Service Line: CADTH Common Drug Review Version: Final Publication

More information

AVXS-101 and Nusinersen for Spinal Muscular Atrophy: Effectiveness and Value

AVXS-101 and Nusinersen for Spinal Muscular Atrophy: Effectiveness and Value AVXS-101 and Nusinersen for Spinal Muscular Atrophy: Effectiveness and Value Background Draft Background and Scope August 22, 2018 Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disease

More information

Measurement of SMN protein in Blood samples Biomarker test for SMA. Thesis. By Hongyang Pi Chemical and Biomolecular Engineering

Measurement of SMN protein in Blood samples Biomarker test for SMA. Thesis. By Hongyang Pi Chemical and Biomolecular Engineering Measurement of SMN protein in Blood samples Biomarker test for SMA Thesis Presented in Partial Fulfillment of the Requirements for the Honors Degree Bachelor of Science in the undergraduate college of

More information

INTERNATIONAL CLINICAL NEUROMUSCULAR FELLOWSHIP PROGRAM

INTERNATIONAL CLINICAL NEUROMUSCULAR FELLOWSHIP PROGRAM INTERNATIONAL CLINICAL NEUROMUSCULAR FELLOWSHIP PROGRAM PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENTS IN NEUROMUSCULAR DISORDERS: IMPLEMENTING STANDARDS OF CARE Program Director: Valeria A Sansone

More information

Nusinersen Demonstrates Efficacy in Infants With and Without Permanent Ventilation: Final Results From the ENDEAR Study

Nusinersen Demonstrates Efficacy in Infants With and Without Permanent Ventilation: Final Results From the ENDEAR Study 2017 Annual Spinal Muscular Atrophy Conference June 29 July 2, 2017 Orlando, FL Nusinersen Demonstrates Efficacy in Infants With and Without Permanent Ventilation: Final Results From the ENDEAR Study Richard

More information

AdvaMed Medtech Value Assessment Framework in Practice

AdvaMed Medtech Value Assessment Framework in Practice AdvaMed Medtech Value Assessment Framework in Practice Application of the Medtech Value Assessment Framework to Cymedica s e-vive System Value Framework Overview In response to the growing need to demonstrate

More information

Clinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327

Clinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327 Clinical Policy: (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

2-1-1 as Gateway to Better Health Outcomes for Young Children

2-1-1 as Gateway to Better Health Outcomes for Young Children 2-1-1 as Gateway to Better Health Outcomes for Young Children AIRS Conference, May 24, 2017 Patricia Herrera, MS 2-1-1 Los Angeles County Bergen Nelson, MD, MS Children s Hospital of Richmond Virginia

More information

Guidelines for exercise and orthoses in children with neuromuscular disorders

Guidelines for exercise and orthoses in children with neuromuscular disorders Guidelines for exercise and orthoses in children with neuromuscular disorders These guidelines were drawn following a workshop held in Newcastle 2002. Several experts from different disciplines including

More information

Developmental Screening in Wisconsin

Developmental Screening in Wisconsin Developmental Screening in Wisconsin Community of Practice on Autism February 10, 2010 Christine M. Breunig, Program Administrator, NE Regional Center - CYSHCN Mala Mathur, MD, Group Health Cooperative

More information

Final Phase 3 Study Data Show SPINRAZA (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy

Final Phase 3 Study Data Show SPINRAZA (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy MEDIA CONTACT: Biogen Ligia Del Bianco Ph: +1 781 464 3260 public.affairs@biogen.com INVESTOR CONTACT: Biogen Ben Strain Ph: +1 781 464 2442 IR@biogen.com Final Phase 3 Study Data Show SPINRAZA (nusinersen)

More information

TREAT-NMD Care and Trial Sites Registry Information Chart

TREAT-NMD Care and Trial Sites Registry Information Chart TREAT-NMD Care and Trial Sites Registry Information Chart Below you find a list of the information that is asked in the CTSR of all registered neuromuscular disease sites. For more information please visit

More information

Jessica Cardenas 1 Melissa Menier 1 Marjet D. Heitzer 1 Douglas M. Sproule 1

Jessica Cardenas 1 Melissa Menier 1 Marjet D. Heitzer 1 Douglas M. Sproule 1 PharmacoEconomics - Open https://doi.org/10.1007/s41669-018-0093-0 ORIGINAL RESEARCH ARTICLE High Healthcare Resource Use in Hospitalized Patients with a Diagnosis of Spinal Muscular Atrophy Type 1 (SMA1):

More information

Type I- Optimal Care for SMA Annual SMA Conference Disneyland Hotel, Anaheim, CA June 16, 2016

Type I- Optimal Care for SMA Annual SMA Conference Disneyland Hotel, Anaheim, CA June 16, 2016 Type I- Optimal Care for SMA 2016 Annual SMA Conference Disneyland Hotel, Anaheim, CA June 16, 2016 Panel Mary Schroth, MD Garey Noritz, MD Rebecca Hurst Davis, MS, RD, CSP, CD Vanessa Battista, RN, MS,

More information

Making a Plan and Lining Up Your Care Team. Kathi Kinnett, MSN, APRN SVP Clinical Care Amanda Weiglein, BSN, RN Manager Clinical Care

Making a Plan and Lining Up Your Care Team. Kathi Kinnett, MSN, APRN SVP Clinical Care Amanda Weiglein, BSN, RN Manager Clinical Care Making a Plan and Lining Up Your Care Team Kathi Kinnett, MSN, APRN SVP Clinical Care Amanda Weiglein, BSN, RN Manager Clinical Care What is a Care Team Complex diagnosis Things change over the lifespan

More information

2016 Rehabilitation Services. Rehabilitation Services Profile at The Ohio State University Wexner Medical Center Dodd Rehabilitation Hospital

2016 Rehabilitation Services. Rehabilitation Services Profile at The Ohio State University Wexner Medical Center Dodd Rehabilitation Hospital 2016 Rehabilitation Services Rehabilitation Services Profile at The Ohio State University Wexner Medical Center Dodd Rehabilitation Hospital The Nation s Best Right Here in Central Ohio Accredited by CARF

More information

New England QIN-QIO Patient and Family Advisor Council. 2017: A Year in Review

New England QIN-QIO Patient and Family Advisor Council. 2017: A Year in Review New England QIN-QIO Patient and Family Advisor Council 2017: A Year in Review The Origins The Center for Medicare & Medicaid Services (CMS) is at the forefront of the nationwide effort to: transform health

More information

Update on Pulmonary Management in Spinal Muscular Atrophy type 1

Update on Pulmonary Management in Spinal Muscular Atrophy type 1 Update on Pulmonary Management in Spinal Muscular Atrophy type 1 David Zielinski, MD FRCPC, FCCP Associate Professor McGill University Montreal Children s Hospital None Disclosures Objectives Review genetic

More information

COMPASS. A Publication Dedicated to Research Updates SUMMER Cure SMA Awards 10 New Grants in Basic Research

COMPASS. A Publication Dedicated to Research Updates SUMMER Cure SMA Awards 10 New Grants in Basic Research COMPASS A Publication Dedicated to Research Updates Cure SMA Awards 10 New Grants in Basic Research In this issue of Compass, we are proud to announce over $1.03 million in new funding. Basic Research

More information

2017 Rehabilitation Services. Rehabilitation Services Profile at The Ohio State University Wexner Medical Center Dodd Rehabilitation Hospital

2017 Rehabilitation Services. Rehabilitation Services Profile at The Ohio State University Wexner Medical Center Dodd Rehabilitation Hospital 2017 Rehabilitation Services Rehabilitation Services Profile at The Ohio State University Wexner Medical Center Dodd Rehabilitation Hospital The Nation s Best Right Here in Central Ohio Accredited by CARF

More information

Cure SMA Awareness & Advocacy Kit

Cure SMA Awareness & Advocacy Kit About Cure SMA Cure SMA is dedicated to the treatment and cure of spinal muscular atrophy (SMA) a disease that takes away a person s ability to walk, eat, or breathe. It is the number one genetic cause

More information

CURRICULUM VITAE. Patricia Navarro McGee, PT, DPT, PCS

CURRICULUM VITAE. Patricia Navarro McGee, PT, DPT, PCS CURRICULUM VITAE Patricia Navarro McGee, PT, DPT, PCS Date July 1, 2017 Contact Information Program in Physical Therapy Washington University School of Medicine 4444 Forest Park Avenue 63108 Phone: (314)

More information

COMPANY OVERVIEW. June 2016

COMPANY OVERVIEW. June 2016 COMPANY OVERVIEW June 2016 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements, including: statements about: the timing, progress and results of preclinical studies

More information

The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS.

The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. HEALTH FACTS The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. Alzheimer s Association Nebraska Chapter 5.5 million

More information

Newborn Screening for Severe Combined Immunodeficiency (SCID) by Quantifying T-cell Receptor Excision Circles (TREC)

Newborn Screening for Severe Combined Immunodeficiency (SCID) by Quantifying T-cell Receptor Excision Circles (TREC) Newborn Screening for Severe Combined Immunodeficiency (SCID) by Quantifying T-cell Receptor Excision Circles (TREC) Patricia R. Slev, PhD, D(ABCC) Medical Director, Serologic Hepatitis and Retrovirus

More information

CHRONIC CONDITIONS FYI

CHRONIC CONDITIONS FYI CHRONIC CONDITIONS FYI AIDS More than 2,500 cases of HIV/AIDS have been identified in Nebraska. Nationwide, this number is more than 1.2 million. ALS (Amyotrophic Lateral Sclerosis) There are 87 people

More information

Genetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome

Genetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome Genetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome It s about knowing. Prenatal testing is not about telling you what s wrong, it s knowing that everything is

More information

Clinical Significance of Strap Tension Adjustment on Spinal Orthoses for Neuromuscular Scoliosis

Clinical Significance of Strap Tension Adjustment on Spinal Orthoses for Neuromuscular Scoliosis Clinical Significance of Strap Tension Adjustment on Spinal Orthoses for Neuromuscular Scoliosis 神 力 臨 領 : NSC 93-2213-E-002-075 行 : 93/08/01 ~ 94/12/31 行 良 Abstract Background: Individuals with neuromuscular

More information

Assessing the Infant and Child with Spinal Muscular Atrophy. Why Assessment Matters. Course Objectives. Introduction to SMA 10/3/2017

Assessing the Infant and Child with Spinal Muscular Atrophy. Why Assessment Matters. Course Objectives. Introduction to SMA 10/3/2017 Assessing the Infant and Child with Spinal Muscular Atrophy Becca Oschwald, PT, DPT Oct. 14, 2017 Why Assessment Matters New drug therapies for SMA Spinraza (nusinersen) First FDA approved treatment for

More information

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy The new england journal of medicine Original Article versus Sham in Infantile-Onset Spinal Muscular Atrophy R.S. Finkel, E. Mercuri, B.T. Darras, A.M. Connolly, N.L. Kuntz, J. Kirschner, C.A. Chiriboga,

More information

International Registries: The Government-Driven Model

International Registries: The Government-Driven Model International Registries: The Government-Driven Model Pål Surén Norwegian Institute of Public Health Presentation outline Overview of Norwegian health registries The Norwegian Mother and Child Cohort Study

More information

DMD STANDARDS OF CARE

DMD STANDARDS OF CARE DMD STANDARDS OF CARE PPMD 2019 END DUCHENNE TOUR Russell Butterfield MD, PhD Director, Muscular Dystrophy Clinics Associate Professor University of Utah, School of Medicine February 2, 2019 DISCLOSURES

More information

SALSA MLPA KIT P060-B2 SMA

SALSA MLPA KIT P060-B2 SMA SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the

More information

DOSAGE FORMS AND STRENGTHS Injection: 12 mg/5 ml (2.4 mg/ml) in a single-dose vial (3)

DOSAGE FORMS AND STRENGTHS Injection: 12 mg/5 ml (2.4 mg/ml) in a single-dose vial (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPINRAZA safely and effectively. See full prescribing information for SPINRAZA. SPINRAZA (nusinersen)

More information

CHRONIC CONDITIONS FYI

CHRONIC CONDITIONS FYI CHRONIC CONDITIONS FYI AIDS More than 2,500 cases of HIV/AIDS have been identified in Nebraska. ALS (Amyotrophic Lateral Sclerosis) Approximately 95 people in Nebraska have ALS. As many as 800 Nebraskans

More information

Innovator Case Studies: Oncology Networks

Innovator Case Studies: Oncology Networks Innovator Case Studies: Oncology Networks J. Ike Nicoll Chief Executive Officer Cancer Clinics of Excellence Alan Armer, Ph.D. Vice President, Research & Development Catholic Health Initiatives Cancer

More information

Date January 20, Contact Information

Date January 20, Contact Information Curriculum Vitae Deborah Golant Badawi, MD Medical Director, Office of Genetics and People with Special Health Care Needs Maryland Department of Health and Mental Hygiene Date January 20, 2016 Contact

More information

Genetic Conditions and Services: An Introduction

Genetic Conditions and Services: An Introduction Genetic Conditions and Services: An Introduction Jennifer Roberts, MC, MS, CGC Laboratory Genetics Counselor The Children s Mercy Hospital, 2017 Goals Determine which children/families may benefit from

More information

Internship Research Mentors Updated (listed in alphabetical order)

Internship Research Mentors Updated (listed in alphabetical order) Internship Research Mentors Updated 9-1- 15 (listed in alphabetical order) Carla Allan, PhD Ongoing/planned projects: Collaboration with genomics, identifying candidate genes to predict treatment response

More information

MARCH Funding the Miracles: Best Practices for Managing Spinraza and Other Orphan Drugs Archimedes, LLC. All Rights Reserved

MARCH Funding the Miracles: Best Practices for Managing Spinraza and Other Orphan Drugs Archimedes, LLC. All Rights Reserved MARCH 27 Funding the Miracles: Best Practices for Managing Spinraza and Other Orphan Drugs 27 Archimedes, LLC. All Rights Reserved Spinraza Overview In a development described by patient advocates as an

More information

Physical Therapist Assistant Principles of Neuromuscular Rehabilitation

Physical Therapist Assistant Principles of Neuromuscular Rehabilitation Western Technical College 10524144 Physical Therapist Assistant Principles of Neuromuscular Rehabilitation Course Outcome Summary Course Information Description Career Cluster Instructional Level Total

More information

Understanding Late-Onset Pompe Disease

Understanding Late-Onset Pompe Disease Understanding Late-Onset Pompe Disease What Is a Lysosome? Millions of tiny units called cells make up the human body. Each cell has its own job to keep the body running. Within each cell, there are organelles,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Genetic Testing for Duchenne and Becker Muscular Dystrophy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_duchenne_and_becker_muscular_dystrophy

More information

SPINRAZA READINESS KIT

SPINRAZA READINESS KIT SPINRAZA READINESS KIT Please see full Prescribing Information for Important Safety Information. MANAGEMENT OF THE REIMBURSEMENT PROCESS FOR SPINRAZA 1 SELECT TREATMENT AFTER DISCUSSING BENEFITS AND RISKS

More information

The first and only treatment for spinal muscular atrophy (SMA)

The first and only treatment for spinal muscular atrophy (SMA) Discover SPINRAZA The first and only treatment for spinal muscular atrophy (SMA) INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

More information

Family Health, Nottingham Children s Hospital Date of submission February 2018

Family Health, Nottingham Children s Hospital Date of submission February 2018 Nusinersen Title of Guideline Guideline for the prescribing and administration of Nusinersen to patients with Spinal Muscular Atrophy Type 1 Contact Name and Job Title (author) Dr Gabriel Chow- Consultant

More information

Mullen Scales of Early Learning: AGS Edition

Mullen Scales of Early Learning: AGS Edition Overview The Mullen Scales of Early Learning: AGS Edition (Mullen, 1995) is an individually administered, standardized measure of cognitive functioning designed to be used with children from birth through

More information

PROJECT PERIODIC REPORT

PROJECT PERIODIC REPORT PROJECT PERIODIC REPORT Project acronym: Project full title: Grant agreement no: CuPiD Closed-loop system for personalized and at-home rehabilitation of people with Parkinson's Disease ICT 288516 Project

More information